These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

366 related items for PubMed ID: 7992072

  • 1. High-dose ifosfamide/carboplatin/etoposide with autologous hematopoietic stem cell support: safety and future directions.
    Elias AD, Ayash LJ, Wheeler C, Schwartz G, Tepler I, McCauley M, Mazanet R, Schnipper L, Frei E, Antman KH.
    Semin Oncol; 1994 Oct; 21(5 Suppl 12):83-5. PubMed ID: 7992072
    [Abstract] [Full Text] [Related]

  • 2. Phase I study of high-dose ifosfamide, carboplatin and etoposide with autologous hematopoietic stem cell support.
    Elias AD, Ayash LJ, Wheeler C, Schwartz G, Tepler I, Gonin R, McCauley M, Mazanet R, Schnipper L, Frei E.
    Bone Marrow Transplant; 1995 Mar; 15(3):373-9. PubMed ID: 7599561
    [Abstract] [Full Text] [Related]

  • 3. High-dose ifosfamide/carboplatin/etoposide: maximum tolerable doses, toxicities, and hematopoietic recovery after autologous stem cell reinfusion.
    Fields KK, Elfenbein GJ, Perkins JB, Janssen WE, Ballester OF, Hiemenz JW, Zorsky PE, Kronish LE, Foody MC.
    Semin Oncol; 1994 Oct; 21(5 Suppl 12):86-92. PubMed ID: 7527592
    [Abstract] [Full Text] [Related]

  • 4. A phase I dose escalation study of multicyclic, dose-intensive chemotherapy with peripheral blood stem cell support for small cell lung cancer.
    Takahashi M, Yoshizawa H, Tanaka H, Tanaka J, Kagamu H, Ito K, Shimbo T, Chou D, Wakabayashi M, Suzuki E, Sakai K, Arakawa M, Gejyo F.
    Bone Marrow Transplant; 2000 Jan; 25(1):5-11. PubMed ID: 10654007
    [Abstract] [Full Text] [Related]

  • 5. Dose escalation of the hypoxic cell sensitizer etanidazole combined with ifosfamide, carboplatin, etoposide, and autologous hematopoietic stem cell support.
    Elias AD, Wheeler C, Ayash LJ, Schwartz G, Ibrahim J, Mills L, McCauley M, Coleman N, Warren D, Schnipper L, Antman KH, Teicher BA, Frei E.
    Clin Cancer Res; 1998 Jun; 4(6):1443-9. PubMed ID: 9626461
    [Abstract] [Full Text] [Related]

  • 6. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB.
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [Abstract] [Full Text] [Related]

  • 7. Ifosfamide, carboplatin, etoposide, and paclitaxel chemotherapy: a dose-escalation study.
    Chang AY, Boros L, Garrow GC, Asbury RF, Hui L.
    Semin Oncol; 1996 Jun; 23(3 Suppl 6):74-7. PubMed ID: 8677454
    [Abstract] [Full Text] [Related]

  • 8. Use of high-dose etoposide/ifosfamide/carboplatin/epirubicin and peripheral blood progenitor cell transplantation in limited-disease small cell lung cancer.
    Brugger W, Frommhold H, Pressler K, Mertelsmann R, Kanz L.
    Semin Oncol; 1995 Feb; 22(1 Suppl 2):3-8. PubMed ID: 7531368
    [Abstract] [Full Text] [Related]

  • 9. High-dose chemotherapy with carboplatin, etoposide and ifosfamide followed by autologous stem cell rescue in patients with relapsed or refractory malignant lymphomas: a phase I/II study.
    Kleiner S, Kirsch A, Schwaner I, Kingreen D, Schwella N, Huhn D, Siegert W.
    Bone Marrow Transplant; 1997 Dec; 20(11):953-9. PubMed ID: 9422474
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Two novel high-dose treatment regimens for metastatic breast cancer--ifosfamide, carboplatin, plus etoposide and mitoxantrone plus thiotepa: outcomes and toxicities.
    Fields KK, Elfenbein GJ, Perkins JB, Hiemenz JW, Janssen WE, Zorsky PE, Ballester OF, Kronish LE, Foody MC.
    Semin Oncol; 1993 Oct; 20(5 Suppl 6):59-66. PubMed ID: 8211217
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Nephrotoxicity after high-dose carboplatin, etoposide and ifosfamide in germ-cell tumors: incidence and implications for hematologic recovery and clinical outcome.
    Beyer J, Rick O, Weinknecht S, Kingreen D, Lenz K, Siegert W.
    Bone Marrow Transplant; 1997 Nov; 20(10):813-9. PubMed ID: 9404920
    [Abstract] [Full Text] [Related]

  • 14. Paclitaxel-based high-dose chemotherapy with autologous stem cell rescue for relapsed germ cell cancer.
    Margolin KA, Doroshow JH, Frankel P, Chow W, Leong LA, Lim D, McNamara M, Morgan RJ, Shibata S, Somlo G, Twardowski P, Yen Y, Kogut N, Schriber J, Alvarnas J, Stalter S.
    Biol Blood Marrow Transplant; 2005 Nov; 11(11):903-11. PubMed ID: 16275593
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The role of hematopoietic growth factors in support of ifosfamide/carboplatin/etoposide chemotherapy.
    Crawford J, George M.
    Semin Oncol; 1995 Jun; 22(3 Suppl 7):18-22. PubMed ID: 7541916
    [Abstract] [Full Text] [Related]

  • 17. High-dose ifosfamide, carboplatin and etoposide with autologous peripheral blood progenitor cell transplantation for small-cell lung cancer.
    Bessho A, Ueoka H, Kiura K, Tabata M, Sunami K, Katayama Y, Yamane H, Hiraki A, Harada M.
    Anticancer Res; 1999 Jun; 19(1B):693-8. PubMed ID: 10216478
    [Abstract] [Full Text] [Related]

  • 18. Feasibility and usefulness of high-dose chemotherapy (high-dose ifosfamide, carboplatin and etoposide) combined with peripheral blood stem cell transplantation for male germ cell tumor: a single-institute experience.
    Hara I, Miyake H, Yamada Y, Yamanaka K, Furukawa J, Kumano M, Takenaka A, Fujisawa M.
    Anticancer Drugs; 2006 Oct; 17(9):1057-66. PubMed ID: 17001179
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Combination therapy with carboplatin/cisplatin/ifosfamide/etoposide in ovarian cancer.
    Lund B, Hansen OP, Hansen HH, Hansen M.
    Semin Oncol; 1992 Feb; 19(1 Suppl 1):26-9. PubMed ID: 1411618
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.